Table 3.
Clinical trials of mRNA vaccine mediated by DC vaccines.
| Company or Institution |
Delivery Vehicle |
Tumor Types | Antigens | Phase | Status | NCT Number |
|---|---|---|---|---|---|---|
| Oslo University Hospital | Not mentioned | Prostate cancer | - | Phase I/II | Completed | NCT01278914 |
| Inge Marie Svane | Not mentioned | Breast cancer Malignant melanoma |
Survivin, hTERT, p53 | Phase I | Completed | NCT00978913 |
| Oslo University Hospital | Not mentioned | Glioblastoma Brain tumor |
Tumor stem cell | Phase I/II | Completed | NCT00846456 |
| Oslo University Hospital | Not mentioned | Prostate cancer | hTERT, Survivin | Phase I/II | Active, not recruiting |
NCT01197625 |
| Radboud University | Electroporated | Uveal melanoma | Tyrosinase, gp100 | Phase I/II | Terminated | NCT00929019 |
| National Cancer Institute | Not mentioned | Leukemia | - | Phase I | Terminated | NCT00514189 |
| Steinar Aamdal | Not mentioned | Recurrent epithelial ovarian cancer | hTERT, survivin | Phase I/II | Terminated | NCT01334047 |
| Steinar Aamdal | Not mentioned | Metastatic malignant melanoma | hTERT, survivin | Phase I/II | Terminated | NCT00961844 |
| Trinomab Biotech Co., Ltd. | Not mentioned | Brain cancer, neoplasm metastases | - | Phase I | Unknown | NCT02808416 |
| University of Florida | Not mentioned | Metastatic prostate cancer | hTERT | Phase I/II | Withdrawn | NCT01153113 |
| Inge Marie Svane | Electroporated | Prostatic neoplasms | PSA, PAP, survivin, hTERT | Phase II | Completed | NCT01446731 |
| Radboud University | Electroporated | Colorectal cancer, liver Metastases | Carcinoembryonic antigen | Phase I/II | Completed | NCT00228189 |
| National Cancer Institute | Not mentioned | Recurrent central nervous, system neoplasm |
Brain tumor stem cell-specific mRNA | Phase I | Completed | NCT00890032 |
| University Hospital, Antwerp | Not mentioned | Glioblastoma, renal cell carcinoma, sarcomas, breast cancers, malignant mesothelioma, colorectal tumors | WT1 protein | Phase I/II | Unknown | NCT01291420 |
| Memorial Sloan Kettering Cancer Center | Electroporated | Melanoma | Tumor-associated antigen | Phase I | Active, not recruiting |
NCT01456104 |
| Affiliated Hospital to Academy of Military Medical Sciences | Not mentioned | Esophagus cancer | MUC1, survivin | Phase I/II | Unknown | NCT02693236 |
| National Cancer Institute | Not mentioned | Malignant neoplasms of brain | pp65-LAMP | Phase I | Active, not recruiting |
NCT00639639 |
| University Hospital, Antwerp | Electroporated | Acute myeloid leukemia | Wilms’ tumor antigen 1 | Phase I | Completed | NCT00834002 |
| Life Research Technologies GmbH | Not mentioned | Ovarian epithelial cancer | TERT- | Phase I | Unknown | NCT01456065 |
| Memorial Sloan Kettering Cancer Center | Electroporated | Multiple myeloma | CT7, MAGE-A3, WT1 | Phase I | Active, not recruiting |
NCT01995708 |
| Radboud University | Not mentioned | Melanoma stage III or IV | gp100 and tyrosinase | Phase I/II | Completed | NCT00243529 |
| Radboud University | Electroporated | Hematological malignancies | Minor histocompatibility antigens | Phase I/II | Completed | NCT02528682 |
| National Cancer Institute | Not mentioned | Malignant neoplasms brain | Cytomegalovirus (CMV) pp65-lysosome-associated membrane protein (LAMP) | Phase I | Completed | NCT00626483 |
| Zwi Berneman | Electroporated | Acute myeloid leukemia | Wilms’ tumor antigen (WT1) | Phase II | Recruiting | NCT01686334 |
| CureVac AG | Not mentioned | Non-small-cell lung cancer | - | Phase I/II | Completed | NCT00923312 |
| Radboud University | Protamine | Prostatic neoplasms | - | Phase II | Completed | NCT02692976 |
| Oslo University Hospital | Not mentioned | Glioblastoma | Survivin and hTERT | Phase II/III | Recruiting | NCT03548571 |
| Ludwig Maximilian University of Munich | Electroporated | Acute myeloid leukemia | WT1, PRAME, CMVpp65 | Phase I/II | Completed | NCT01734304 |
| University Hospital, Antwerp | Electroporated | Malignant pleural mesothelioma | Wilms’ tumor protein 1 (WT1) | Phase I/II | Recruiting | NCT02649829 |
| Asterias Biotherapeutics, Inc. | Not mentioned | Acute myelogenous leukemia | hTERT and a portion of the lysosome-associated membrane protein (LAMP-1) | Phase II | Completed | NCT00510133 |
| Oslo University Hospital | Not mentioned | Malignant melanoma | - | Phase I/II | Completed | NCT01278940 |
| Radboud University | Electroporated | Melanoma | gp100 and tyrosinase | Phase I/II | Completed | NCT01530698 |
| University Hospital, Antwerp | Electroporated | High-grade glioma, diffuse intrinsic pontine glioma | WT1 | Phase I/II | Recruiting | NCT04911621 |
| Radboud University | Electroporated | Melanoma | gp100 and tyrosinase | Phase I/II | Completed | NCT00940004 |
| Bart Neyns | Electroporated | Melanoma | - | Phase I | Completed | NCT01066390 |
| Radboud University | Electroporated | Melanoma | gp100 and tyrosinase | Phase II | Completed | NCT02285413 |
| Immunomic Therapeutics, Inc. | Electroporated | Glioblastoma multiforme, glioblastoma, malignant glioma, astrocytoma, grade IVGBM | pp65-shLAMP | Phase II | Recruiting | NCT02465268 |
| University Hospital, Antwerp | Electroporated | Glioblastoma multiforme of brain | WT1 | Phase I/II | Recruiting | NCT02649582 |
| Gary Archer, Ph.D. | Not mentioned | Glioblastoma | Human CMV pp65-LAMP | Phase II | Recruiting | NCT03688178 |
| University Hospital, Antwerp | Electroporated | Acute myeloid leukemia | WT1 | Phase I | Completed | NCT00834002 |
| Gary Archer, Ph.D. | Electroporated | Glioblastoma | Human CMV pp65-LAMP | Phase II | Suspended | NCT03927222 |
| Universitair Ziekenhuis Brussel | Electroporated | Malignant melanoma | - | Phase II | Completed | NCT01676779 |
| Guangdong 999 Brain Hospital | Not mentioned | Glioblastoma | Personalized TAAs | Phase I | Active, Not recruiting |
NCT02808364 |